Point mutation in c-HA-ras oncogene in normal and abnormal cells

Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas

N- and K-ras mutations at codons 12 and 13 were investigated using oligonucleotide hybridization analysis after PCR amplification and subsequent sequence analysis of the amplified DNA from the region of interest in the following prostatic primary and metastatic (met) carcinoma-derived cell lines: 1013L (primary), PC3 (bone met), DU145 (brain met), and LNCaP (lymph node met). We also examined fresh and archival primary and metastatic prostate tumor tissue and benign prostatic hypertrophy specimens. All prostatic cells and tissues examined contain at least one wild-type N- and K-ras allele with respect to codons 12 and 13. No mutations were found at N-ras codon 13. The only mutation seen in the prostatic cell lines and tissues was a K-ras codon 12 position II G-to-T transversion. Since these are established nonclonal cell lines that have adapted to tissue culture, it is possible that this mutation does not represent the mutational state of prostatic carcinoma in vivo. However, the lack of consistent mutation in the ras genes amplified directly from tumors suggests that when ras mutations occur during the progression of prostatic carcinoma, they are late-stage events not directly involved in the initial development of disease. Immunoprecipitation studies using pan-ras antibodies revealed no evidence of altered expression of Ras proteins.

Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP

We have investigated the structure and expression of the c-myc proto-oncogene in DNA isolated from the immortal cell line LNCaP. This cell line was derived from a lymph node metastasis of human prostate cancer. Msp I digest of LNCaP DNA when hybridized to a human c-myc probe showed a 1.45 kb band of intensity about two-fold greater than that observed in normal lymphocytes. In addition, the LNCaP cells contain rearranged and amplified c-myc structures which are not present in normal lymphocytes. Quantitation of these bands by scanning densitometry is consistent with an approximately 10-fold amplification of c-myc. To determine whether this amplification was accompanied by increased expression, RNA was isolated from these cells and compared to RNA isolated from a control cell line in which c-myc was not amplified. Northern blot analysis showed that the RNA transcripts from LNCaP cells were approximately 50-fold higher. Although androgens modulate the cell growth of LNCaP, there was no change in the level of c-myc RNA transcripts in serum-free medium in the presence or absence of androgens. Further investigation to determine whether altered structure, amplification, and overexpression of c-myc constitute a common characteristic of metastatic human prostate cancer might prove profitable in understanding this disease.